 Connection
Judith Regensteiner to Follow-Up Studies
This is a "connection" page, showing publications Judith Regensteiner has written about Follow-Up Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.279 |
|
|
|
-
Kao DP, Martin JL, Aquilante CL, Shalowitz EL, Leyba K, Kudron E, Reusch JEB, Regensteiner JG. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration. BMJ Open Diabetes Res Care. 2024 Dec 05; 12(6).
Score: 0.122
-
Scalzo RL, Moreau KL, Ozemek C, Herlache L, McMillin S, Gilligan S, Huebschmann AG, Bauer TA, Dorosz J, Reusch JE, Regensteiner JG. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. J Diabetes Complications. 2017 Feb; 31(2):449-455.
Score: 0.069
-
Scherer SA, Hiatt WR, Regensteiner JG. Lack of relationship between gait parameters and physical function in peripheral arterial disease. J Vasc Surg. 2006 Oct; 44(4):782-8.
Score: 0.035
-
Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Goldberg S, Jaff MR, Steffes MW, Comerota AJ, Ehrman J, Treat-Jacobson D, Walsh ME, Collins T, Badenhop DT, Bronas U, Hirsch AT. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012 Jan 03; 125(1):130-9.
Score: 0.012
-
Murphy TP, Hirsch AT, Cutlip DE, Regensteiner JG, Comerota AJ, Mohler E, Cohen DJ, Massaro J. Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg. 2009 Oct; 50(4):942-945.e2.
Score: 0.011
-
Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006 Sep; 29(9):2102-7.
Score: 0.009
-
Hiatt WR, Klepack E, Nehler M, Regensteiner JG, Blue J, Imus J, Criqui MH. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vasc Med. 2004 Nov; 9(4):271-7.
Score: 0.008
-
Rajagopalan S, Olin JW, Young S, Erikson M, Grossman PM, Mendelsohn FO, Regensteiner JG, Hiatt WR, Annex BH. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther. 2004 Jun; 15(6):619-24.
Score: 0.007
-
Cooper LT, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, Cooke JP, Hirsch AT. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med. 2001 Nov; 6(4):235-9.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|